Bibliography
- Karberg S. Biotech's perfect storm. Cell 2009;3:413-15
- McCamish M, Woollett G. The state of the art in the development of biosimilars. Clin Pharmacol Ther 2012;91(3):405-17
- Rovira J, Espín J, García L, et al. The impact of biosimilars' entry in the EU market. EMINET. 2011. Available from: http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_market_012011_en.p
- Grillberger L, Kreil TR, Nasr S, et al. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J 2009;4(2):186-201
- Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use
- Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 2004;15:398-406
- Ebbers HC, Crow SA, Vulto AG, et al. Interchangeability, immunogenicity and biosimilars. Nat Biotechnol 2012;30:1186-90
- European Medicines Agency – Scientific Guidelines – Multidisciplinary – Biosimilars. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000408.jsp&mid=WC0b01ac058002958c [Last accessed 7 June 2013]
- Food and Drug Administration- Biosimilars. Available from: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm [Last accessed 7 June 2013]
- Aranesp™. Procedural steps taken and scientific information after the authorization. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000332/WC500026145.pdf [Last accessed 7 February June 2013]
- Tysabri™. Procedural steps taken and scientific information after the authorization. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000603/WC500044692.pdf [Last accessed 7 June 2013]
- ICH Topic Q 8 (R2) - Pharmaceutical Development. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002872.pdf [Last accessed 7 June 2013]
- Perjeta™ CHMP Opinion. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002547/smops/Positive/human_smop_000457.jsp&mid=WC0b01ac058001d127 [Last accessed 7 June 2013]
- Wang J, Chow SC. On the regulatory pathway of biosimilar products. Pharmaceuticals 2012;5:353-68